文献速递银屑病与炎症性皮肤病

布罗达鲁单抗临床研究中的免疫原性与皮损清除再捕获

Immunogenicity and skin clearance recapture in clinical studies of brodalumab.
PubMed 文献 · J Am Acad Dermatol · 2019-06-05

该分析基于1项2期和3项3期布罗达鲁单抗治疗银屑病的研究,评估抗药抗体对安全性、疗效和再治疗的影响。结果显示结合型抗药抗体阳性率2.7%,无中和性抗体;ADA阳性患者第12周sPGA 0/1应答率60.0%(3/5),ADA阴性患者79.1%(1131/1429);再治疗患者全部达到PASI 75改善。

要点

  • 布罗达鲁单抗结合型抗药抗体阳性率2.7%,无中和性抗体。
  • ADA阳性患者第12周sPGA 0/1应答率60.0%(3/5),ADA阴性79.1%(1131/1429)。
  • 再治疗患者100%达到PASI 75,≥90%在再治疗第8周前恢复应答。

核心结论

  • 布罗达鲁单抗免疫原性较低,再治疗时疗效再捕获率高。

研究设计与样本

  • 分析1项2期和3项3期布罗达鲁单抗治疗银屑病研究的数据。

主要发现

  • 结合型抗药抗体阳性率2.7%,一过性占1.4%,无中和性抗体。
  • ADA阳性患者第12周sPGA 0/1应答率60.0%(3/5),ADA阴性患者79.1%(1131/1429)。
  • 再治疗患者100%达到PASI 75,≥90%在再治疗第8周前恢复应答。
  • 超敏反应发生率低于安慰剂,注射部位反应1.8% vs 乌司奴单抗2%。

临床怎么用

  • 布罗达鲁单抗免疫原性低,再治疗时多数患者可快速恢复疗效。

局限性

  • 再治疗评估仅来自1项3期研究。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Antidrug antibodies (ADAs) may change pharmacokinetic or pharmacodynamic profiles of biologic therapies, potentially decreasing efficacy. OBJECTIVE: To evaluate the potential effects of brodalumab immunogenicity on safety, efficacy, and retreatment. METHODS: Data from 1 phase 2 and 3 phase 3 studies of brodalumab in psoriasis were analyzed. RESULTS: Overall, 2.7% of patients had positive test results for binding ADAs after receiving brodalumab; ADAs were transient in 1.4% of patients, and there were no neutralizing ADAs. Among ADA-positive patients, 60.0% (3/5) achieved a static physician's global assessment score of 0 or 1 at week 12 in the group receiving the brodalumab 210 mg every 2 weeks, compared with 79.1% (1131/1429) of ADA-negative patients. All patients (100%) who experienced return of disease and were retreated with brodalumab 210 mg every 2 weeks (none were ADA positive) achieved at least a 75% improvement in Psoriasis Area And Severity Index, ≥90% of whom regained response by week 8 of retreatment. Hypersensitivity reactions were less frequent with brodalumab than with placebo. Injection site reactions occurred in 1.8% of patients treated with brodalumab versus 2% of patients treated with ustekinumab. LIMITATIONS: Retreatment could be assessed in only 1 phase 3 brodalumab study. CONCLUSION: Brodalumab compares favorably with other biologics in terms of immunogenicity and high rates of efficacy recapture upon retreatment.

来源:J Am Acad Dermatol,查看原文。版权归原作者所有。

引用

  1. Bagel J, Lebwohl M, Israel RJ, et al. Immunogenicity and skin clearance recapture in clinical studies of brodalumab. J Am Acad Dermatol. 2019. PMID: 31175910. doi:10.1016/j.jaad.2019.05.094

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。